The oligonucleotide synthesis market size is estimated to increase by USD 2,870.69 million from 2022 to 2027. The market’s growth momentum will progress at a CAGR of 13.47%. Discover some insights on market size historic period (2017 to 2021) and Forecast (2023 to 2027) before buying the full report –Request a sample report
Oligonucleotide synthesis market – Vendor Analysis
Vendor Landscape – The global oligonucleotide synthesis market is fragmented, with the presence of several global as well as regional vendors. A few prominent vendors that offer oligonucleotide synthesis in the market are Agilent Technologies Inc., Ajinomoto Co. Inc., Alnylam Pharmaceuticals Inc., Bio Synthesis Inc, Biocon Ltd., Biotage AB, Danaher Corp., Eurofins Scientific SE, General Electric Co., Ionis Pharmaceuticals Inc., Kaneka Corp., LGC Science Group Holdings Ltd., Maravai LifeSciences Holdings Inc., Merck KGaA, Mettler Toledo International Inc., QIAGEN NV, Sarepta Therapeutics Inc, Synbio Technologies, Thermo Fisher Scientific Inc., and Biogen Inc. and others.
What’s New? –
- Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession
- Global competitiveness and key competitor positions
- Market presence across multiple geographical footprints – Strong/Active/Niche/Trivial – Buy the report!
Vendor Offerings –
- Agilent Technologies Inc – The company offers oligonucleotide synthesis products such as SurePrint HiFi.
- Biotage AB. – The company offers oligonucleotide synthesis for drug manufacturing.
- Alnylam Pharmaceuticals Inc. – The company offers oligonucleotide synthesis such as RNAi.
- For details on the vendor and its offerings – Request a sample report
Oligonucleotide Synthesis Market – Segmentation Assessment
Segment Overview
Technavio has segmented the market based on application (PCR primers, Flurorescence in situ hybridization, PCR assays and panels, DNA microarrays, and Others), end-user (Pharmaceutical and biotechnology companies, Research and academic institutes, Diagnostic laboratories, and Hospitals), and geography (North America, Europe, Asia, and Rest of World (ROW)).
- The market share growth by the PCR Primers segment will be significant during the forecast period. PCR primers are short oligonucleotide sequences specifically designed to target and initiate the amplification process in PCR reactions, playing a crucial role in various applications like gene expression analysis, DNA sequencing, and mutation detection. The demand for PCR primers is particularly high in high-throughput applications, such as large-scale genotyping or DNA sequencing projects. Oligonucleotide synthesis companies are capable of synthesizing a large number of PCR primers simultaneously to support these high-throughput applications, contributing to the growth of the PCR primers segment in the Global oligonucleotide Synthesis Market during the forecast period.
Geography Overview
By geography, the global oligonucleotide synthesis market is segmented into North America, Europe, Asia, and Rest of World (ROW). The report provides actionable insights and estimates the contribution of all regions to the growth of the global oligonucleotide synthesis market.
- North America is estimated to account for 43% of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. With the US leading the regional market, North America dominates the regional oligonucleotide synthesis market. The adoption of synthetic nucleic acids for research, therapeutic applications, and diagnosis is driven by the presence of a leading market. In the US, vendors are using advanced technologies and methodologies to meet the growing demand for oligonucleotides.
FOR INSIGHTS ON GLOBAL, REGIONAL, AND COUNTRY-LEVEL PARAMETERS WITH GROWTH OPPORTUNITIES FROM 2017 TO 2027 – DOWNLOAD A SAMPLE REPORT
Oligonucleotide Synthesis Market – Market Dynamics
Leading Drivers
The increasing research activities in the pharmaceutical and biotechnology sectors are notably driving market growth. The rising prevalence of chronic and life-threatening diseases is driving the demand for pharmaceutical and biotechnological research, leading to the development of effective therapeutics and diagnostic techniques. Advances in life sciences research have improved our understanding of biological systems, resulting in increased use of genetic engineering technologies. Oligonucleotide synthesis technologies have become essential in molecular-level development, design, and modification of biological systems for pharmaceutical and biotechnology researchers. Recombinant protein production, facilitated by oligonucleotide synthesis, enables the analysis of functional and structural aspects of therapeutic monoclonal antibodies and target proteins. Oligonucleotides, particularly as primers, have revolutionized research in disease processes and gene expression through antisense oligonucleotide technology. This approach, focusing on inhibiting translation to limit protein synthesis, has contributed to the development of various treatments for conditions like familial hypercholesterolemia and cytomegalovirus retinitis. These factors are anticipated to drive the growth of the global oligonucleotide synthesis market during the forecast period.
Key Trends
The rise in demand for low-cost and high-throughput oligonucleotide synthesis is an emerging trend shaping market growth. The large-scale production of desired gene sequences at a lower cost could contribute to fast improvement in both applied biological research and fundamental. The cost of oligonucleotide synthesis since genetic material is made from oligonucleotides which are directly proportional to the costs of gene synthesis. The reduction of the oligonucleotide synthesis costs makes it possible to develop a more efficient set of gene data. Thus, there is a growing demand for techniques and technologies that permits the synthesis of oligonucleotides and their assembly into larger DNA constructs with expanded sequence fidelity at a lowered cost. The significant costs of gene synthesis are also associated with reagents that are applied for oligonucleotide synthesis. Therefore, there is rising demand for methods and tools that lower reagent consumption, improve the robustness and precision of the gene assembly process, and improve throughput in oligonucleotide synthesis. These factors are anticipated to drive the growth of the oligonucleotide synthesis market during the forecast period.
Major challenges
The diversity in oligonucleotide molecules is a major challenge hindering market growth. Generally, oligonucleotides are larger molecules than conventional small molecules used in therapeutics. Effective uptake of oligonucleotides in a targeted location determines the success of drug candidates. Nevertheless, the diversity within the classes of therapeutics in terms of the size of the molecule and range of chemical modification necessitates careful consideration before nucleic acid synthesis. In addition, as compared to complex molecules, the availability of fewer target sites permits small molecules to be modified in a limited manner. For this reason, in order to manage the different mechanisms of action and features of these molecules, it is necessary that all oligonucleotide types are considered carefully. Due to undetected impurity and toxicity, the complexity and diversity in oligonucleotide molecules rise the propensity for performance failure of drug candidates. Consequently, non-compliance with regulatory requirements can adversely affect drug manufacturers. such factors are expected to impede market growth over the forecast period.
Find more insights from a sample report!
What are the key data covered in this Oligonucleotide Synthesis Market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the oligonucleotide synthesis market between 2023 and 2027
- Precise estimation of the Oligonucleotide Synthesis Market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behaviour
- Growth of the oligonucleotide synthesis market across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of oligonucleotide synthesis market vendors
Gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
Related Reports:
The ibuprofen active pharmaceutical ingredient (API) market is estimated to grow at a CAGR of 2.53% between 2022 and 2027. The size of the market is forecasted to increase by USD 31.68 million. This report extensively covers market segmentation by end-user (pharmaceutical companies and contract manufacturing organizations), product (prescription and over-the-counter), and geography (Asia, North America, Europe, and Rest of World (ROW). The increasing geriatric population is notably driving the ibuprofen active pharmaceutical ingredient (API) market growth.
The Global Active Pharmaceutical Ingredients (API) Market size is estimated to grow by USD 88.74 billion between 2022 and 2027 accelerating at a CAGR of 7.24%. This report extensively covers market segmentation by manufacturing type (captive APIs and contract APIs), type (innovative APIs and generic APIs), and geography (Asia, North America, Europe, and Rest of World (ROW)). The increasing number of type II drug master files (DMFs) is notably driving the active pharmaceutical ingredients market growth.
| Oligonucleotide Synthesis Market Scope | |
| Report Coverage | Details |
| Historic period | 2017-2021 |
| Forecast period | 2023-2027 |
| Growth momentum & CAGR | Accelerate at a CAGR of 13.47% |
| Market growth 2023-2027 | USD 2,870.69 million |
| Market structure | Fragmented |
| YoY growth 2022-2023 (%) | 13.31 |
| Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution | North America at 43% |
| Key countries | US, Canada, Germany, China, and Japan |
| Competitive landscape | Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
| Key companies profiled | Agilent Technologies Inc., Ajinomoto Co. Inc., Alnylam Pharmaceuticals Inc., Bio Synthesis Inc, Biocon Ltd., Biotage AB, Danaher Corp., Eurofins Scientific SE, General Electric Co., Ionis Pharmaceuticals Inc., Kaneka Corp., LGC Science Group Holdings Ltd., Maravai LifeSciences Holdings Inc., Merck KGaA, Mettler Toledo International Inc., QIAGEN NV, Sarepta Therapeutics Inc, Synbio Technologies, Thermo Fisher Scientific Inc., and Biogen Inc. |
| Market dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of contents
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global oligonucleotide synthesis market 2017 – 2021
- Exhibit 18: Historic Market Size – Data Table on global oligonucleotide synthesis market 2017 – 2021 ($ million)
- 4.2 Applications Segment Analysis 2017 – 2021
- Exhibit 19: Historic Market Size – Applications Segment 2017 – 2021 ($ million)
- 4.3 End-user Segment Analysis 2017 – 2021
- Exhibit 20: Historic Market Size – End-user Segment 2017 – 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 – 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
- 4.5 Country Segment Analysis 2017 – 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
6 Market Segmentation by Application
- 6.1 Market segments
- Exhibit 30: Chart on Application – Market share 2022-2027 (%)
- Exhibit 31: Data Table on Application – Market share 2022-2027 (%)
- 6.2 Comparison by Application
- Exhibit 32: Chart on Comparison by Application
- Exhibit 33: Data Table on Comparison by Application
- 6.3 PCR primers – Market size and forecast 2022-2027
- Exhibit 34: Chart on PCR primers – Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on PCR primers – Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on PCR primers – Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on PCR primers – Year-over-year growth 2022-2027 (%)
- 6.4 Fluorescence in situ hybridization – Market size and forecast 2022-2027
- Exhibit 38: Chart on Fluorescence in situ hybridization – Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Fluorescence in situ hybridization – Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Fluorescence in situ hybridization – Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Fluorescence in situ hybridization – Year-over-year growth 2022-2027 (%)
- 6.5 PCR assays and panels – Market size and forecast 2022-2027
- Exhibit 42: Chart on PCR assays and panels – Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on PCR assays and panels – Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on PCR assays and panels – Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on PCR assays and panels – Year-over-year growth 2022-2027 (%)
- 6.6 DNA microarrays – Market size and forecast 2022-2027
- Exhibit 46: Chart on DNA microarrays – Market size and forecast 2022-2027 ($ million)
- Exhibit 47: Data Table on DNA microarrays – Market size and forecast 2022-2027 ($ million)
- Exhibit 48: Chart on DNA microarrays – Year-over-year growth 2022-2027 (%)
- Exhibit 49: Data Table on DNA microarrays – Year-over-year growth 2022-2027 (%)
- 6.7 Others – Market size and forecast 2022-2027
- Exhibit 50: Chart on Others – Market size and forecast 2022-2027 ($ million)
- Exhibit 51: Data Table on Others – Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Chart on Others – Year-over-year growth 2022-2027 (%)
- Exhibit 53: Data Table on Others – Year-over-year growth 2022-2027 (%)
- 6.8 Market opportunity by Application
- Exhibit 54: Market opportunity by Application ($ million)
- Exhibit 55: Data Table on Market opportunity by Application ($ million)
7 Market Segmentation by End-user
- 7.1 Market segments
- Exhibit 56: Chart on End-user – Market share 2022-2027 (%)
- Exhibit 57: Data Table on End-user – Market share 2022-2027 (%)
- 7.2 Comparison by End-user
- Exhibit 58: Chart on Comparison by End-user
- Exhibit 59: Data Table on Comparison by End-user
- 7.3 Pharmaceutical and biotechnology companies – Market size and forecast 2022-2027
- Exhibit 60: Chart on Pharmaceutical and biotechnology companies – Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Pharmaceutical and biotechnology companies – Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Pharmaceutical and biotechnology companies – Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Pharmaceutical and biotechnology companies – Year-over-year growth 2022-2027 (%)
- 7.4 Research and academic institutes – Market size and forecast 2022-2027
- Exhibit 64: Chart on Research and academic institutes – Market size and forecast 2022-2027 ($ million)
- Exhibit 65: Data Table on Research and academic institutes – Market size and forecast 2022-2027 ($ million)
- Exhibit 66: Chart on Research and academic institutes – Year-over-year growth 2022-2027 (%)
- Exhibit 67: Data Table on Research and academic institutes – Year-over-year growth 2022-2027 (%)
- 7.5 Diagnostic laboratories – Market size and forecast 2022-2027
- Exhibit 68: Chart on Diagnostic laboratories – Market size and forecast 2022-2027 ($ million)
- Exhibit 69: Data Table on Diagnostic laboratories – Market size and forecast 2022-2027 ($ million)
- Exhibit 70: Chart on Diagnostic laboratories – Year-over-year growth 2022-2027 (%)
- Exhibit 71: Data Table on Diagnostic laboratories – Year-over-year growth 2022-2027 (%)
- 7.6 Hospitals – Market size and forecast 2022-2027
- Exhibit 72: Chart on Hospitals – Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Data Table on Hospitals – Market size and forecast 2022-2027 ($ million)
- Exhibit 74: Chart on Hospitals – Year-over-year growth 2022-2027 (%)
- Exhibit 75: Data Table on Hospitals – Year-over-year growth 2022-2027 (%)
- 7.7 Market opportunity by End-user
- Exhibit 76: Market opportunity by End-user ($ million)
- Exhibit 77: Data Table on Market opportunity by End-user ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 78: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 79: Chart on Market share by geography 2022-2027 (%)
- Exhibit 80: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 81: Chart on Geographic comparison
- Exhibit 82: Data Table on Geographic comparison
- 9.3 North America – Market size and forecast 2022-2027
- Exhibit 83: Chart on North America – Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on North America – Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on North America – Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on North America – Year-over-year growth 2022-2027 (%)
- 9.4 Europe – Market size and forecast 2022-2027
- Exhibit 87: Chart on Europe – Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on Europe – Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on Europe – Year-over-year growth 2022-2027 (%)
- 9.5 Asia – Market size and forecast 2022-2027
- Exhibit 91: Chart on Asia – Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on Asia – Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on Asia – Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
- Exhibit 95: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- 9.7 US – Market size and forecast 2022-2027
- Exhibit 99: Chart on US – Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on US – Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on US – Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on US – Year-over-year growth 2022-2027 (%)
- 9.8 China – Market size and forecast 2022-2027
- Exhibit 103: Chart on China – Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on China – Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on China – Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on China – Year-over-year growth 2022-2027 (%)
- 9.9 Germany – Market size and forecast 2022-2027
- Exhibit 107: Chart on Germany – Market size and forecast 2022-2027 ($ million)
- Exhibit 108: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
- Exhibit 109: Chart on Germany – Year-over-year growth 2022-2027 (%)
- Exhibit 110: Data Table on Germany – Year-over-year growth 2022-2027 (%)
- 9.10 Canada – Market size and forecast 2022-2027
- Exhibit 111: Chart on Canada – Market size and forecast 2022-2027 ($ million)
- Exhibit 112: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
- Exhibit 113: Chart on Canada – Year-over-year growth 2022-2027 (%)
- Exhibit 114: Data Table on Canada – Year-over-year growth 2022-2027 (%)
- 9.11 Japan – Market size and forecast 2022-2027
- Exhibit 115: Chart on Japan – Market size and forecast 2022-2027 ($ million)
- Exhibit 116: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
- Exhibit 117: Chart on Japan – Year-over-year growth 2022-2027 (%)
- Exhibit 118: Data Table on Japan – Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 119: Market opportunity by geography ($ million)
- Exhibit 120: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 121: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 122: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 123: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 124: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 125: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 126: Matrix on vendor position and classification
- 12.3 Agilent Technologies Inc.
- Exhibit 127: Agilent Technologies Inc. – Overview
- Exhibit 128: Agilent Technologies Inc. – Business segments
- Exhibit 129: Agilent Technologies Inc. – Key offerings
- Exhibit 130: Agilent Technologies Inc. – Segment focus
- 12.4 Alnylam Pharmaceuticals Inc.
- Exhibit 131: Alnylam Pharmaceuticals Inc. – Overview
- Exhibit 132: Alnylam Pharmaceuticals Inc. – Product / Service
- Exhibit 133: Alnylam Pharmaceuticals Inc. – Key news
- Exhibit 134: Alnylam Pharmaceuticals Inc. – Key offerings
- 12.5 Biogen Inc.
- Exhibit 135: Biogen Inc. – Overview
- Exhibit 136: Biogen Inc. – Product / Service
- Exhibit 137: Biogen Inc. – Key offerings
- 12.6 Biotage AB
- Exhibit 138: Biotage AB – Overview
- Exhibit 139: Biotage AB – Product / Service
- Exhibit 140: Biotage AB – Key news
- Exhibit 141: Biotage AB – Key offerings
- 12.7 Danaher Corp.
- Exhibit 142: Danaher Corp. – Overview
- Exhibit 143: Danaher Corp. – Business segments
- Exhibit 144: Danaher Corp. – Key news
- Exhibit 145: Danaher Corp. – Key offerings
- Exhibit 146: Danaher Corp. – Segment focus
- 12.8 Eurofins Scientific SE
- Exhibit 147: Eurofins Scientific SE – Overview
- Exhibit 148: Eurofins Scientific SE – Business segments
- Exhibit 149: Eurofins Scientific SE – Key news
- Exhibit 150: Eurofins Scientific SE – Key offerings
- Exhibit 151: Eurofins Scientific SE – Segment focus
- 12.9 Ionis Pharmaceuticals Inc.
- Exhibit 152: Ionis Pharmaceuticals Inc. – Overview
- Exhibit 153: Ionis Pharmaceuticals Inc. – Business segments
- Exhibit 154: Ionis Pharmaceuticals Inc. – Key news
- Exhibit 155: Ionis Pharmaceuticals Inc. – Key offerings
- Exhibit 156: Ionis Pharmaceuticals Inc. – Segment focus
- 12.10 Kaneka Corp.
- Exhibit 157: Kaneka Corp. – Overview
- Exhibit 158: Kaneka Corp. – Business segments
- Exhibit 159: Kaneka Corp. – Key offerings
- Exhibit 160: Kaneka Corp. – Segment focus
- 12.11 LGC Science Group Holdings Ltd.
- Exhibit 161: LGC Science Group Holdings Ltd. – Overview
- Exhibit 162: LGC Science Group Holdings Ltd. – Product / Service
- Exhibit 163: LGC Science Group Holdings Ltd. – Key offerings
- 12.12 Maravai LifeSciences Holdings Inc.
- Exhibit 164: Maravai LifeSciences Holdings Inc. – Overview
- Exhibit 165: Maravai LifeSciences Holdings Inc. – Business segments
- Exhibit 166: Maravai LifeSciences Holdings Inc. – Key offerings
- Exhibit 167: Maravai LifeSciences Holdings Inc. – Segment focus
- 12.13 Merck KGaA
- Exhibit 168: Merck KGaA – Overview
- Exhibit 169: Merck KGaA – Business segments
- Exhibit 170: Merck KGaA – Key news
- Exhibit 171: Merck KGaA – Key offerings
- Exhibit 172: Merck KGaA – Segment focus
- 12.14 Mettler Toledo International Inc.
- Exhibit 173: Mettler Toledo International Inc. – Overview
- Exhibit 174: Mettler Toledo International Inc. – Business segments
- Exhibit 175: Mettler Toledo International Inc. – Key offerings
- Exhibit 176: Mettler Toledo International Inc. – Segment focus
- 12.15 Sarepta Therapeutics Inc
- Exhibit 177: Sarepta Therapeutics Inc – Overview
- Exhibit 178: Sarepta Therapeutics Inc – Product / Service
- Exhibit 179: Sarepta Therapeutics Inc – Key offerings
- 12.16 Synbio Technologies
- Exhibit 180: Synbio Technologies – Overview
- Exhibit 181: Synbio Technologies – Product / Service
- Exhibit 182: Synbio Technologies – Key offerings
- 12.17 Thermo Fisher Scientific Inc.
- Exhibit 183: Thermo Fisher Scientific Inc. – Overview
- Exhibit 184: Thermo Fisher Scientific Inc. – Business segments
- Exhibit 185: Thermo Fisher Scientific Inc. – Key news
- Exhibit 186: Thermo Fisher Scientific Inc. – Key offerings
- Exhibit 187: Thermo Fisher Scientific Inc. – Segment focus
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 188: Inclusions checklist
- Exhibit 189: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 190: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 191: Research methodology
- Exhibit 192: Validation techniques employed for market sizing
- Exhibit 193: Information sources
- 13.5 List of abbreviations
- Exhibit 194: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio